Thao Phuong Thi Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thao Phuong Thi Pham has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anh Tuan Lai
Nam Dinh Center for Disease Control, Nam Dinh 420000, Vietnam
1 shared publication - Dang Duc Anh
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
1 shared publication - Ha Ngoc Hoang
Nam Dinh General Hospital, Nam Dinh 420000, Vietnam
1 shared publication - Ho Huu Thien
Central Hue Hospital, Thua Thien Hue 530000, Vietnam
1 shared publication - Hung Hoang Pham
Central Hue Hospital, Thua Thien Hue 530000, Vietnam
1 shared publication - Jacqueline E. Tate
Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, USA
1 shared publication
Latest Publications
- Open Access
Intussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces—Vietnam, 2017–2021
Rotavin-M1 (POLYVAC) was licensed in Vietnam in 2012. The association of Rotavin-M1 with intussusception, a rare adverse event associated with rotavirus vaccines, and with adverse events following immunization (AEFI) have not been evaluated and monitored under conditions of routine use. From February 2017 to May 2021, we conducted a pilot introduction of Rotavin-M1 into the routine vaccination program in two provinces. Surveillance for intussusception was conducted at six sentinel hospitals. AEFI reports at 30 min and 7 days after vaccination were recorded. Among 443 children ®, ComBE Five®) compared to Rotavin-M1 without pentavalent vaccines. There was no association between intussusception and Rotavin-M1. The vaccine was generally safe when administered alone and when co-administered with other vaccines.
Open AccessIntussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces—Vietnam, 2017–2021
Rotavin-M1 (POLYVAC) was licensed in Vietnam in 2012. The association of Rotavin-M1 with intussusception, a rare adverse event associated with rotavirus vaccines, and with adverse events following immunization (AEFI) have not been evaluated and monitored under conditions of routine use. From February 2017 to May 2021, we conducted a pilot introduction of Rotavin-M1 into the routine vaccination program in two provinces. Surveillance for intussusception was conducted at six sentinel hospitals. AEFI reports at 30 min and 7 days after vaccination were recorded. Among 443 children ®, ComBE Five®) compared to Rotavin-M1 without pentavalent vaccines. There was no association between intussusception and Rotavin-M1. The vaccine was generally safe when administered alone and when co-administered with other vaccines.